Format
Sort by

Send to

Choose Destination

Search results

Items: 18

1.

Anti-TNFα treatment for recalcitrant ulcerative necrobiosis lipoidica diabeticorum: A case report and review of the literature.

Basoulis D, Fragiadaki K, Tentolouris N, Sfikakis PP, Kokkinos A.

Metabolism. 2016 Apr;65(4):569-73. doi: 10.1016/j.metabol.2015.12.014. Epub 2016 Jan 7.

PMID:
26975548
2.

Rheumatoid arthritis is sufficient to cause atheromatosis but not arterial stiffness or hypertrophy in the absence of classical cardiovascular risk factors.

Arida A, Zampeli E, Konstantonis G, Fragiadaki K, Kitas GD, Protogerou AD, Sfikakis PP.

Clin Rheumatol. 2015 May;34(5):853-9. doi: 10.1007/s10067-015-2914-1. Epub 2015 Mar 11.

PMID:
25754335
3.

Chemerin and cardiovascular risk in rheumatoid arthritis after interleukin 6 receptor blockade.

Makrilakis K, Fragiadaki K, Sfikakis PP, Kitas GD.

J Rheumatol. 2015 Feb;42(2):349. doi: 10.3899/jrheum.141115. No abstract available.

PMID:
25641970
4.

Cadherin-11 mRNA transcripts are frequently found in rheumatoid arthritis peripheral blood and correlate with established polyarthritis.

Sfikakis PP, Christopoulos PF, Vaiopoulos AG, Fragiadaki K, Katsiari C, Kapsimali V, Lallas G, Panayiotidis P, Korkolopoulou P, Koutsilieris M.

Clin Immunol. 2014 Nov;155(1):33-41. doi: 10.1016/j.clim.2014.08.008. Epub 2014 Aug 27.

PMID:
25173800
5.

Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade.

Makrilakis K, Fragiadaki K, Smith J, Sfikakis PP, Kitas GD.

Clin Rheumatol. 2015 Mar;34(3):419-27. doi: 10.1007/s10067-014-2704-1. Epub 2014 Jun 10.

PMID:
24912961
6.

Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study.

Zampeli E, Protogerou A, Stamatelopoulos K, Fragiadaki K, Katsiari CG, Kyrkou K, Papamichael CM, Mavrikakis M, Nightingale P, Kitas GD, Sfikakis PP.

Arthritis Res Ther. 2012 Mar 5;14(2):R44. doi: 10.1186/ar3757.

7.

Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis.

Fragiadaki K, Tektonidou MG, Konsta M, Chrousos GP, Sfikakis PP.

J Rheumatol. 2012 Jan;39(1):60-2. doi: 10.3899/jrheum.110617. Epub 2011 Dec 1.

PMID:
22133618
8.

Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.

Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis PP.

Clin Exp Rheumatol. 2011 Nov-Dec;29(6):921-5. Epub 2011 Dec 22.

PMID:
22032557
9.

A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis.

Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP.

Atherosclerosis. 2011 Dec;219(2):734-6. doi: 10.1016/j.atherosclerosis.2011.09.015. Epub 2011 Sep 16.

PMID:
21968316
10.

Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.

Karanikolas GN, Koukli EM, Katsalira A, Arida A, Petrou D, Komninou E, Fragiadaki K, Zacharioudaki A, Lasithiotakis I, Giavri E, Vaiopoulos G, Sfikakis PP.

J Rheumatol. 2011 Nov;38(11):2466-74. doi: 10.3899/jrheum.110242. Epub 2011 Sep 1.

PMID:
21885499
11.

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.

Arida A, Fragiadaki K, Giavri E, Sfikakis PP.

Semin Arthritis Rheum. 2011 Aug;41(1):61-70. doi: 10.1016/j.semarthrit.2010.09.002. Epub 2010 Dec 17. Review.

PMID:
21168186
12.

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP.

Rheumatology (Oxford). 2011 Mar;50(3):593-7. doi: 10.1093/rheumatology/keq366. Epub 2010 Nov 21.

13.

Orbital lobular panniculitis in Weber-Christian disease: sustained response to anti-TNF treatment and review of the literature.

Mavrikakis I, Georgiadis T, Fragiadaki K, Sfikakis PP.

Surv Ophthalmol. 2010 Nov-Dec;55(6):584-9. doi: 10.1016/j.survophthal.2010.05.001. Epub 2010 Aug 10. Review.

PMID:
20701939
14.

Subclinical peripheral arterial disease in rheumatoid arthritis.

Stamatelopoulos KS, Kitas GD, Papamichael CM, Kyrkou K, Zampeli E, Fragiadaki K, Panoulas VF, Mavrikakis M, Sfikakis PP.

Atherosclerosis. 2010 Sep;212(1):305-9. doi: 10.1016/j.atherosclerosis.2010.05.007. Epub 2010 May 12.

PMID:
20553683
15.

Glutamate levels and activity of the T cell voltage-gated potassium Kv1.3 channel in patients with systemic lupus erythematosus.

Poulopoulou C, Papadopoulou-Daifoti Z, Hatzimanolis A, Fragiadaki K, Polissidis A, Anderzanova E, Davaki P, Katsiari CG, Sfikakis PP.

Arthritis Rheum. 2008 May;58(5):1445-50. doi: 10.1002/art.23446.

16.

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.

Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, Stefanadis C, Mavrikakis M.

Arthritis Rheum. 2007 Jun;56(6):1985-93.

17.

Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.

Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN.

Clin Immunol. 2007 Apr;123(1):66-73. Epub 2007 Jan 31.

PMID:
17275413
18.

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM.

Arthritis Rheum. 2005 Feb;52(2):501-13.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk